trending Market Intelligence /marketintelligence/en/news-insights/trending/efghkn1g64vrmjmdje9nog2 content esgSubNav
In This List

Portola Pharmaceuticals chief commercial/business officer resigns

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Portola Pharmaceuticals chief commercial/business officer resigns

Portola Pharmaceuticals Inc. said Tao Fu resigned as executive vice president and chief commercial and business officer, effective Sept. 21, to pursue other opportunities.

South San Francisco, Calif.-based Portola said that Interim co-President and CFO Mardi Dier will lead its commercial activities, including the ongoing launches of blood disorder therapies Andexxa and Bevyxxa.

Fu will remain as a consultant until March 1, 2019, to assist in the transition.

The company said in a Sept. 7 news release that it has hired an executive search firm for recruiting a new CEO and chief commercial officer. Portola's CEO retired in August.

Portola is a biopharmaceutical company that develops and commercializes therapeutics relating to blood clotting and other blood disorders.